Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 70
- Locations
- 2
- Primary Endpoint
- the number of days of analgesic use for headache
Study Overview
Brief Summary
The aim of this study to evaluate pre-injection patient-related factors that may influence treatment response in patients with medication-overuse headache who underwent ultrasound-guided greater occipital nerve block.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age between 18 and 65 years
- •Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)
- •Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs
- •Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria
Exclusion Criteria
- •History of severe head or neck trauma or previous neurosurgical intervention
- •Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)
- •History of infectious disease, chronic inflammatory disease, or malignancy
- •Previous diagnosis of secondary headache
- •History of substance abuse
- •Pregnancy or breastfeeding
- •History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)
- •Difficulty with cooperation
- •Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)
Arms & Interventions
Treatment success group
Patients who demonstrated a ≥50% reduction in the number of days of analgesic use for headache at the end of the second-month evaluation
Intervention: Treatment outcome (Other)
Treatment failure group
Patients who demonstrated a <50% reduction in the number of days of analgesic use for headache at the end of the second-month evaluation
Intervention: Treatment outcome (Other)
Outcomes
Primary Outcomes
the number of days of analgesic use for headache
Time Frame: Baseline
Patients will be questioned the total number of days on which they used analgesics for headache during the past month.
Secondary Outcomes
- Headache severity(Baseline)
- Post-injection pain severity(Baseline)
- Headache-related disability(Baseline)
- Pressure pain threshold(Baseline)
- Anxiety and depression levels(Baseline)
- Sleep quality(Baseline)
Investigators
Alper Mengi
Associate Professor
Sultan 1. Murat State Hospital